• Precision BioSciences scheduled an investor webcast on May 27, 2026 to discuss new biopsy and clinical findings from its ongoing Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B.
• The biopsy data were selected as a late-breaking presentation at the European Association for the Study of the Liver Congress 2026 in Barcelona on May 27, 2026, with a separate clinical update set for release once the conference embargo lifts.
• The update signals the program has generated new human evidence intended to support the investment case for PBGENE-HBV, though specific results were not disclosed in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260521616212) on May 21, 2026, and is solely responsible for the information contained therein.